Evaluation of the Interaction Between Low Dose Sulfamethoxazole-Trimethoprim and Zidovudine

Inclusion Criteria

Prior Medication:

Allowed:

• Zidovudine (AZT) for patients with AIDS.
• AIDS related complex (ARC). The presence of any one of the following findings within 12 months prior to entry and the absence of a concurrent illness or conditions other than HIV infection to explain the findings:
• Fever of > 38.5 C degrees persisting for longer than 3 weeks.
• Involuntary weight loss of > 15 lbs. or > 10 percent of baseline noted in a 120-day period prior to evaluation.
• Diarrhea (> 2 liquid stools per day) persisting for longer than 1 month.
• History of clinical diagnosis of oral candidiasis or hairy leukoplakia.
• Patients who have AIDS-defining opportunistic infections or tumors.
• Patients eligible for AZT under the labeling.
• A positive HIV antibody test. Exceptions will be made for patients with a previously positive HIV antibody test with progressive disease and patients where virus isolation has been made.
• A life expectancy of at least 3 months.
• Patient with stable Kaposi's sarcoma, mild herpes infection, mild or stable depression, asymptomatic or mild cytomegalovirus or Epstein-Barr virus infection, or a hepatitis B virus carrier state will be acceptable for study.

Exclusion Criteria

Concurrent Medication:

Excluded:

• Phenytoin.

Prior Medication:

Excluded within 30 days of study entry:

• Other antiretroviral agents.
• Patient has any severe ongoing opportunistic infections including Pneumocystis carinii pneumonia (PCP), cryptococcal or toxoplasmosis meningoencephalitis, disseminated herpes simplex or herpes zoster.
• Patient has significant diarrhea at entry ( > 1 watery stool per day).
• Patient has demonstrated prior sensitivity or has experienced significant adverse effects during prior therapy with the drugs to be used in the study.
• Cannot abstain from alcohol or any other drugs during the study.